Zobrazeno 1 - 10
of 1 179
pro vyhledávání: '"measurable residual disease"'
Autor:
Yoshiko Nakano, Ian Burns, Liana Nobre, Robert Siddaway, Mansuba Rana, Cody Nesvick, Andrew Bondoc, Michelle Ku, Richard Yuditskiy, Dennis T. L. Ku, Matthew M. K. Shing, Kevin K. F. Cheng, Ho-Keung Ng, Anirban Das, Julie Bennett, Vijay Ramaswamy, Annie Huang, David Malkin, Birgit Ertl-Wagner, Peter Dirks, Eric Bouffet, Ute Bartels, Uri Tabori, Cynthia Hawkins, Anthony P. Y. Liu
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-10 (2024)
Abstract Central nervous system germ cell tumors (CNS-GCT) are malignant neoplasms that arise predominantly during adolescence and young adulthood. These tumors are typically sensitive to treatment, but resulting long-term health deficits are common.
Externí odkaz:
https://doaj.org/article/6648a47c01a041ef973984cd5c1e5f71
Autor:
Carina Maria Pinto, Camila Marques Bertolucci, Alef Rafael Severino, Juliana Fernanda dos Santos Tosi, Maura R V Ikoma-Colturato
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss 4, Pp 542-548 (2024)
Acute megakaryoblastic leukemia is characterized by heterogeneous biology and clinical behavior. Immunophenotypic characteristics include the expression of megakaryocytic differentiation markers (e.g. CD41, CD42a, CD42b, CD61) associated with immatur
Externí odkaz:
https://doaj.org/article/8390c2d59c3447a6a9cfe75afdf758cd
Autor:
Won Kee Ahn, Kyunghee Yu, Hongkyung Kim, Seung-Tae Lee, Jong Rak Choi, Jung Woo Han, Chuhl Joo Lyu, Seungmin Hahn, Saeam Shin
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Assessment of measurable residual disease (MRD) is an essential prognostic tool for B-lymphoblastic leukaemia (B-ALL). In this study, we evaluated the utility of next-generation sequencing (NGS)–based MRD assessment in real-worl
Externí odkaz:
https://doaj.org/article/db7ea2e458184b0a9ef0acb4ef0fcfa3
Autor:
Yi-Lun Wang, Tsung-Yen Chang, Yu-Chuan Wen, Shu-Ho Yang, Yi-Wen Hsiao, Chia-Chi Chiu, Yu-Chieh Chen, Ruei-Shan Hu, Shih-Hsiang Chen, Tang-Her Jaing, Chih-Cheng Hsiao
Publikováno v:
Hematology Reports, Vol 16, Iss 2, Pp 347-353 (2024)
Background/Objectives: Relapsed B-cell acute lymphoblastic leukemia (B-ALL) remains an unresolved matter of concern regarding adverse outcomes. This case study aimed to evaluate the effectiveness of blinatumomab, with or without door lymphocyte infus
Externí odkaz:
https://doaj.org/article/17a0e9cbc111478b9c38291dcd7e97af
Autor:
Lian-Lian Li, Yue-Ping Xia, Qianqian Li, Peng Wang, Ping-Ping Sun, Xing-Guang Wang, Rui Zhang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionChimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising approach for treating relapsed/refractory (r/r) T-cell acute lymphoblastic leukemia (T-ALL). However, it is mostly used as a bridging therapy for allogeneic hemat
Externí odkaz:
https://doaj.org/article/edeebdde399e42b3ba76dec48f22783c
Autor:
Xiaowen Gong, Tianyuan Hu, Qiujin Shen, Luyang Zhang, Wei Zhang, Xueou Liu, Suyu Zong, Xiaoyun Li, Tiantian Wang, Wen Yan, Yu Hu, Xiaoli Chen, Jiarui Zheng, Aoli Zhang, Junxia Wang, Yahui Feng, Chengwen Li, Jiao Ma, Xin Gao, Zhen Song, Yingchi Zhang, Robert Peter Gale, Xiaofan Zhu, Junren Chen
Publikováno v:
eJHaem, Vol 5, Iss 2, Pp 333-345 (2024)
Abstract ETV6::RUNX1 is the most common fusion gene in childhood acute lymphoblastic leukaemia (ALL) and is associated with favorable outcomes, especially in low‐risk children. However, as many as 10% of children relapse within 3 years, and such ea
Externí odkaz:
https://doaj.org/article/2d19a6eea3e6454582900e1f537d85bf
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Purpose: The study aimed to access the impact of related factors on the long-term survival of patients with B-cell acute lymphoblastic leukemia (B-ALL) by analyzing clinical characteristics of B-ALL patients, and observed the significance of dynamic
Externí odkaz:
https://doaj.org/article/e677d82faab24fd183a226c16496e12c
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21978-21984 (2023)
Abstract Background Blinatumomab improved survival outcomes in B‐cell acute lymphoblastic leukemia (B‐ALL) patients with measurable residual disease (MRD)
Externí odkaz:
https://doaj.org/article/d311f07fab204be9bb04345f755162de
Autor:
Jiechen Yu, Yanrong Luo, Libing Wang, Tao Wang, Mingyu Ye, Jie Chen, Xiong Ni, Li Chen, Lei Gao, Jianmin Yang
Publikováno v:
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)
Abstract Background To explore the effects of monitoring measurable residual disease and post‐remission treatment selection on the clinical outcomes of B‐cell acute lymphoblastic leukemia (B‐ALL) in adults. Methods Between September 2010 and Ja
Externí odkaz:
https://doaj.org/article/b7245bc0965a4088b0e4b9bfa0aea76e
Autor:
Sonia Ahmed, Mariam Elsherif, Dina Yassin, Nahla Elsharkawy, Ayman S. Mohamed, Nouran Yasser, Amr Elnashar, Hanafy Hafez, Edward A. Kolb, Alaa Elhaddad
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundMolecular testing plays a pivotal role in monitoring measurable residual disease (MRD) in acute myeloid leukemia (AML), aiding in the refinement of risk stratification and treatment guidance. Wilms tumor gene 1 (WT1) is frequently upregulat
Externí odkaz:
https://doaj.org/article/b8f5691c0581409d84e6d241e1945e4b